Jeil Pharma Holdings Inc (002620.KS) Stock

002620.KS logo

Jeil Pharma Holdings Inc

002620.KSSouth Korea
Healthcare

Company profile

Jeil Pharma reported revenue of 657.61 billion KRW for fiscal year 2025. Its largest business segment, Pharmaceutical Sector, brought in 98% of segment revenue in fiscal year 2024; South Korea was the largest region with 93%. Our analysis of its filings shows revenue shrinking from 804.04 billion KRW in fiscal year 2023 to 657.61 billion KRW in fiscal year 2025, 9.6% a year on average. Jeil Pharma reports about 41 full-time employees.

What stands out

  • Revenue fell 15.7% in fiscal year 2025, from 779.82 billion KRW in fiscal year 2024, after a fall of 3.0% the year before.
  • It returned to a profit in fiscal year 2025, 14.64 billion KRW, after 4 years of net losses (51.16 billion KRW in fiscal year 2024).

Figures from company filings; latest fiscal year ended December 31, 2025.

About Jeil Pharma Holdings Inc

Jeil Pharma Holdings Inc manufactures and sells ingredients of drugs, incrementally modified drugs, and generic drugs in South Korea. The company offers active pharmaceutical ingredients in the areas of antibiotics, gastrointestinal, cardiovascular, neuropsychiatry, oncology, endocrinology, urology, antiviral, and antihistamines, as well as patch products. It also provides finished dosage forms in the areas of anti-bacteria and anti-fungal, anti-virus, cardiovascular, endocrinology, neurology, gastrointestinal, urology, oncology, anti-histamine, rheumatology, respiratory, otolaryngological, heaptic, laxatives, and purgatives. The company exports its products to approximately 40 countries in the Association of Southeast Asian Nations, Central and South America, Africa, etc. The company was founded in 1959 and is headquartered in Seoul, South Korea.

Largest shareholders

  • Seung-Soo Han56.86 %56.86%
  • Sang-Cheol Han10.64 %10.64%
  • Otsuka Holdings Co., Ltd.9.37%
  • Jeil Pharma Holdings Inc3.90%
  • Sang-Woo Han2.854 %2.85%

Share of the company, as of September 25, 2026

Leadership

  • Seung-Soo Han — Chairman of The Board and Chief Executive Officer, 78

How much revenue does Jeil Pharma make?

Jeil Pharma reported 657.61 billion KRW in revenue for fiscal year 2025, down 15.7% from 779.82 billion KRW in fiscal year 2024.

What is Jeil Pharma's largest business segment?

Pharmaceutical Sector, with 794.70 billion KRW or 98% of segment revenue in fiscal year 2024. Next: Investment Sector (2%).

Where does Jeil Pharma make most of its revenue?

South Korea: 93% of revenue by region in fiscal year 2024, followed by Overseas (7%).

What companies are similar to Jeil Pharma?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Ilyang Pharmaceutical Co.,Ltd (007570.KS), Ahn-Gook Pharmaceutical Co., Ltd. (001540.KQ), Handok Inc. (002390.KS), Dong Sung Bio Pharm.Co.,Ltd. (002210.KS).

How has Jeil Pharma's revenue changed over the last 5 fiscal years?

Revenue by fiscal year: FY2021, 762.57 billion KRW; FY2022, 792.96 billion KRW; FY2023, 804.04 billion KRW; FY2024, 779.82 billion KRW; FY2025, 657.61 billion KRW.

Has Jeil Pharma made a profit in recent years?

Net income by fiscal year: FY2021, a loss of 3.48 billion KRW; FY2022, a loss of 74.56 billion KRW; FY2023, a loss of 16.25 billion KRW; FY2024, a loss of 51.16 billion KRW; FY2025, 14.64 billion KRW. It reported a net loss in 4 of these 5 years.

Company Information

SectorHealthcare
IndustryMulti-Therapeutic Drug Manufacturing
Employees41
HeadquartersSeoul, South Korea
ExchangeKSE
TimezoneAsia/Seoul (KST)

Contact & Links

Address
343, Sapyeong-daero, Seoul, 06543
Phone
82 2 549 7451
Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.

Data as of .

How to cite: DataPorium, “Jeil Pharma Holdings Inc (002620.KS)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/002620.KS

LinkedInLinkedInXXYouTubeYouTube